You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.

This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.

Do you wish to leave this site?

Yes No

You are here Identifier : NCT03785184

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

    Status Suspended
    Related Conditions
    Multiple Myeloma

Enrollment Details

40 Worldwide Enrollment Goal


  • 1
  • 2
  • 3
  • 4
Study Type:  Interventional

This is a type II phase trial.

Protocol ID

Brief summary


This study will evaluate the safety and preliminary efficacy of venetoclax when combined with lenalidomide and dexamethasone for participants with newly diagnosed, active t(11;14) positive multiple myeloma (MM).

Participant Attributes :
  • Male and Female
  • Ages 18 ans et plus

Canada: 4

Calgary, AB
Toronto, ON
Montreal, QC
Montreal, QC
Would you like to know more about this trial?

Study Design

  • The general design that describes the strategy for identifying and following up with participants during observational studies.

    Observational Model

    Single group assignment

  • The general design that describes the strategy for identifying and following up with participants during observational studies.


    None (Open Label)

  • This is the single main reason for carrying out the clinical trial. Reasons can include: treatment, prevention, diagnostic advances, supportive care, screening, or health services research, among others.



    • Must have documented, confirmed active multiple myeloma (MM) with greater than or equal to 10% clonal bone marrow plasma cells or biopsy-proven bone or extramedullary plasmacytoma and any one or more of the following myeloma-defining events:
      • Evidence of end organ damage attributed to the underlying plasma cell proliferative disorder and satisfying at least one of the protocol specified laboratory criteria for calcium elevation, renal failure, anemia, or lytic bone lesions; OR
      • One or more of the biomarkers of malignancy as described in the protocol.
    • Must have MM positive for the t(11;14) translocation, as determined by methods described in the protocol.
    • Must have measurable disease defined by at least one of the following criteria:
      • Serum M-protein ≥ 1.0 g/dL (immunoglobulin [Ig]G myeloma) or greater than or equal to 0.5 g/dL (IgA, IgM, IgD, or IgE myeloma);
      • Urine M-protein greater than or equal to 200 mg/24 hours;
      • Serum free light chain (FLC) greater than or equal to 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal.
    • Newly diagnosed and not considered a candidate for high-dose therapy and hematopoietic stem cell transplantation (HSCT)
    • Must have Eastern Cooperative Oncology Group performance status less than or equal to 2.  
    • Has a co-existing condition as specified in the protocol.
    • Has history of other active malignancies, including myelodysplastic syndromes (MDS) within the past 3 years with specific exceptions detailed in the protocol.
    • Has been treated with or received any of the following:
      • Prior or current systemic therapy or hematopoietic stem cell transplantation (HSCT) for MM (a short course of treatment with corticosteroids equivalent to dexamethasone 40 mg/day for a maximum of 4 days is allowed before treatment); use of systemic strong or moderate inhibitor or inducer of cytochrome P450(CYP)3A within 7 days before the first dose of study drug.
      • Radiation therapy within 2 weeks of dosing
      • Plasmapheresis within 4 weeks of dosing
      • Immunization with live vaccine within 8 weeks of dosing
    • Has a contraindication or inability to comply with antithrombotic prophylaxis.

More on this trial

Clinical Trials